KALA BIO Implements 1-for-50 Reverse Stock Split

KALA BIO ( (KALA) ) has issued an announcement.

KALA BIO on May 7, 2026 filed a Certificate of Amendment in Delaware to implement a 1-for-50 reverse stock split of its common stock, effective May 8, 2026, following shareholder approval granted at a meeting held January 30, 2026. The move consolidates every fifty existing shares into one without changing par value, with cash in lieu for fractional shares and no change to the company’s authorized share count.

The reverse split will cut KALA BIO’s outstanding common shares from 929,491,578 to about 18,589,832, while proportionally adjusting equity awards, warrants and plan reserves, and the stock will begin trading on a split-adjusted basis on Nasdaq under the unchanged ticker “KALA” on May 11, 2026. The action is expected to impact the company’s capital structure and share price mechanics but leaves investors’ proportional ownership largely intact, apart from minor effects from fractional share cash-outs and rounding.

The most recent analyst rating on (KALA) stock is a Hold with a $1.50 price target. To see the full list of analyst forecasts on KALA BIO stock, see the KALA Stock Forecast page.

Spark’s Take on KALA Stock

According to Spark, TipRanks’ AI Analyst, KALA is a Neutral.

The score is weighed down primarily by very weak financial performance (zero revenue, persistent losses, and ongoing cash burn) and strongly bearish technicals (price below all key moving averages with negative MACD). A low P/E and a potentially positive AI-platform licensing event provide some offset, but both are secondary to near-term financial sustainability and trend weakness.

To see Spark’s full report on KALA stock, click here.

More about KALA BIO

KALA BIO, Inc. is a clinical-stage biopharmaceutical company developing a proprietary biologics pipeline alongside an AI infrastructure platform for the biotechnology industry. Its portfolio includes an MSC-S (mesenchymal stem cell secretome) platform and product candidates with FDA Orphan Drug and Fast Track designations, paired with a scalable AI platform-as-a-service aimed at secure, on-premises deployment for biotech and pharmaceutical clients.

Through an exclusive worldwide license for the Researgency AI research platform from Younet, Kala positions itself as an AI infrastructure partner for biomedical organizations seeking to leverage proprietary biological data while maintaining control. The company focuses on agentic AI systems via Researgency.ai, emphasizing enterprise security, real-time performance and seamless integration to drive research, documentation and operational workflows in the life sciences sector.

Average Trading Volume: 7,638,859

Technical Sentiment Signal: Sell

Current Market Cap: $107M

For a thorough assessment of KALA stock, go to TipRanks’ Stock Analysis page.